Combining the therapeutic approaches of GLP-1 agonists (which target extrahepatic mechanisms for metabolic disorders) with resmetirom (which target intrahepatic mechanisms for MASH and liver fibrosis) seems like a promising strategy for addressing fat accumulation, inflammation, and fibrosis associated with MASH
Some observational studies have noted that patients with type 2 diabetes and rheumatoid arthritis who were treated with GLP-1 agonists experienced modest reductions in inflammatory markers compared to those on other glucose-lowering therapies
Instead, I recommend saving your money and focusing on proven methods for addressing back pain
I'm seeing a little bit of pathology in your spine maybe that's what's causing your pelvic pain and pain with intercourse and left leg discomfort
[21] Similarly, the combination of lisinopril with aliskiren should be avoided in patients with moderate to severe renal impairment
[1] [3] It works by mimicking the action of the naturally occurring hormone GLP-1, which stimulates insulin secretion in a glucose-dependent manner, suppresses glucagon release, slows gastric emptying, and promotes satiety
